Zhengye Biotechnology Holding Limited
NASDAQ:ZYBTDrug Manufacturers - Specialty & Generic
Healthcare
$1.50 +1047.56%
+$7.31 today
- Market cap
- $71.09M
- Beta
- -2.17
- P/E (TTM)
- -36.3
- EPS (TTM)
- -$1.50
52W Low $0.62High $13.08
Volume 0.02M
Average 0.10M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
$13.33M
FY 2025 · Annual
-67.5% YoYInvesting Cash Flow
-$12.63M
FY 2025 · Annual
Financing Cash Flow
$32.31M
FY 2025 · Annual
Cash Flow Statement
CNY
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 46.47M | 55.74M | 37.51M | 13.47M | (82.97M) |
| Depreciation & Amortization | 16.01M | 18.8M | 23.91M | 24.16M | 25.96M |
| Deferred Income Tax | (358K) | (1.09M) | 758K | 924K | 11.1M |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | (33.71M) | (66.82M) | (20.49M) | (977K) | 44.83M |
| Accounts Receivables | (40.91M) | (47.38M) | 38.05M | 11.31M | 61.41M |
| Inventory | (12.34M) | (12.33M) | (12.9M) | (5.88M) | 6.25M |
| Accounts Payables | 17.63M | (9.67M) | (35.61M) | (404K) | (3.36M) |
| Other Working Capital | 1.91M | 2.56M | (10.03M) | (6M) | (19.47M) |
| Other Non-Cash Items | 3.4M | 10.7M | 6.5M | 3.47M | 14.42M |
| Operating Cash Flow | 31.81M | 17.34M | 48.18M | 41.05M | 13.33M |
| Capital Expenditures | (26.4M) | (27.33M) | (11.6M) | (27.77M) | (12.63M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (1.22M) | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (7.21M) | 0 | (3.15M) | (14.08M) | (11.62M) |
| Investing Cash Flow | (26.27M) | (27.33M) | (11.77M) | (27.67M) | (12.63M) |
| Debt Repayment | 8M | 34.88M | 24.97M | (2.74M) | (12.09M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 43.08M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (11.05M) | (21.43M) | (39.45M) | (16.02M) | 0 |
| Other Financing Activities | 0 | (1) | (4.5M) | (3.37M) | 1.32M |
| Financing Cash Flow | (3.05M) | 13.46M | (18.98M) | (22.13M) | 32.31M |
| Effect of Forex Changes | 0 | 0 | 0 | 168K | (1.29M) |
| Net Change in Cash | 2.49M | 3.46M | 17.44M | (8.58M) | 31.73M |
| Free Cash Flow | 5.41M | (9.99M) | 36.58M | 13.27M | 703K |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$83.0M
+ D&A$26.0M
+ Stock-Based Comp$0
+ Deferred Tax$11.1M
+ Working Capital$44.8M
+ Other Non-Cash$14.4M
= Operating Cash Flow$13.3M
- Capex-$12.6M
= Free Cash Flow$703.0K
Analysis
FY2025 free cash flow is $703.0K. FCF conversion is -0.8% of net income. Operating cash flow was $13.3M, with capex of -$12.6M. The largest bridge item is Working Capital at $44.8M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 12, 2026 | |
| 6-K | 6-K filing | Aug 6, 2026 | |
| 6-K | 6-K filing | Jul 21, 2026 | |
| 3 | Initial statement of beneficial ownership | Jun 25, 2026 | |
| 3 | Initial statement of beneficial ownership | Jun 25, 2026 |
Does ZYBT generate free cash flow?
Zhengye Biotechnology Holding Limited (ZYBT) generated $703,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does ZYBT produce?
Operating cash flow was $13.33M, before capital expenditures of $12.63M.
Continue the stock analysis
Jump to another research area for this company.